|
KMID : 0213520160300050369
|
|
Korean Journal of Ophthalmology
2016 Volume.30 No. 5 p.369 ~ p.376
|
|
|
The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
|
|
Shin Kyung-Hoon
Lee Tae-Gon
Kim Jae-Hui
Kim Jong-Woo
Kim Chul-Gu
Lee Dong-Won
Han Jung-Il
Lew Young-Ju
Cho Han-Joo
|
|
|
Abstract
|
|
|
Purpose: To evaluate the efficacy of intravitreal aflibercept monotherapy in submacular hemorrhage (SMH) secondary to wet age-related macular degeneration (AMD).
Methods: This study included 25 eyes in 25 patients with SMH involving the fovea secondary to wet-AMD. All patients were treated with three consecutive monthly intravitreal aflibercept (2.0 mg/0.05 mL) injections, followed by as-needed reinjection. They were followed for at least 6 months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and area of SMH were measured at diagnosis, as well as at 3 and 6 months after treatment initiation.
Results: The BCVA significantly improved from 0.79 ± 0.41 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.54 ± 0.41 logMAR at 6 months (p < 0.001). BCVA ≥3 lines and stable vision were observed in 96% of the eyes. The CFT significantly decreased from 560.8 ± 215.3 μm at baseline to 299.8 ± 160.2 μm at 6 months (p < 0.001). The area of SMH significantly decreased from 10.5 ± 7.1 mm2 at baseline to 1.8 ± 6.5 mm2 at 6 months (p < 0.001). The BCVA, CFT, and area of SMH at baseline, as well as duration of symptoms, all correlated with BCVA at the 6-month follow-up.
Conclusions: Intravitreal injection of aflibercept is an effective treatment option for patients with SMH secondary to wet-AMD; however, there may be limited efficacy in eyes with large SMH area and cases in which treatment is delayed.
|
|
|
KEYWORD
|
|
|
Aflibercept, Choroidal hemorrhage, Macular degeneration, Retinal hemorrhage
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|